Nurix Therapeutics (NRIX) Chief Legal Officer reports option exercise and stock sales

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. insider transaction: The company’s Chief Legal Officer, identified as the reporting person, exercised an employee stock option to acquire 3,760 shares of Nurix common stock at an exercise price of $1.86 per share on 12/18/2025. The same day, the insider sold 3,560 shares of common stock at a weighted average price of $17.8661 per share and an additional 200 shares at a weighted average price of $18.555 per share.

These transactions were carried out under a previously adopted Rule 10b5-1 trading plan. After these transactions, the reporting person beneficially owned 50,897 shares of Nurix common stock directly and held 12,403 employee stock options. The option exercised on this date had fully vested by August 9, 2023.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/18/2025		M(1)		3,760	A	$1.86	54,657	D
Common Stock	12/18/2025		S(1)		3,560	D	$17.8661(2)	51,097	D
Common Stock	12/18/2025		S(1)		200	D	$18.555(3)	50,897	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.86	12/18/2025		M			3,760	(4)	09/30/2029	Common Stock	3,760	$0	12,403	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $17.53 and the highest price at which shares were sold was $18.18. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $18.55 and the highest price at which shares were sold was $18.56. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

4. The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Nurix Therapeutics (NRIX) report in this Form 4?

The Chief Legal Officer of Nurix Therapeutics, Inc. reported exercising an employee stock option for 3,760 shares at $1.86 per share and selling 3,560 shares at a weighted average price of $17.8661 and 200 shares at a weighted average price of $18.555 on 12/18/2025.

Who is the reporting person in the Nurix Therapeutics (NRIX) Form 4 filing?

The reporting person is an officer of Nurix Therapeutics, Inc., serving as the Chief Legal Officer, and is filing as a single reporting person.

Were the Nurix Therapeutics (NRIX) insider trades made under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected pursuant to a previously adopted Rule 10b5-1 trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

How many Nurix Therapeutics (NRIX) shares does the insider own after these transactions?

Following the reported transactions, the insider beneficially owned 50,897 shares of Nurix common stock directly and held 12,403 employee stock options.

What were the sale prices for the Nurix Therapeutics (NRIX) insider stock sales?

The filing reports a weighted average sale price of $17.8661 per share for 3,560 shares, with individual sale prices ranging from $17.53 to $18.18, and a weighted average sale price of $18.555 per share for 200 shares, with prices ranging from $18.55 to $18.56.

What are the terms of the Nurix Therapeutics (NRIX) employee stock option exercised?

The exercised employee stock option had an exercise price of $1.86 per share, covered 3,760 underlying common shares, and vested 1/4 on September 9, 2020, with the remaining 3/4 vesting in equal monthly installments until it was fully vested on August 9, 2023. The option expires on September 30, 2029.